[1]
|
中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185. https://doi.org/10.3760/cma.j.issn.0578-1426.2020.03.002
|
[2]
|
Arai, A. (2021) Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods. Microorganisms, 9, Article No. 180. https://doi.org/10.3390/microorganisms9010180
|
[3]
|
Fujiwara, S. and Nakamura, H. (2020) Chronic Active Epstein-Barr Virus Infection: Is It Immunodeficiency, Malignancy, or Both? Cancers, 12, Article No. 3202. https://doi.org/10.3390/cancers12113202
|
[4]
|
Jog, N.R., Young, K.A., Munroe, M.E., Harmon, M.T., Guthridge, J.M., Kelly, J.A., et al. (2019) Association of Epstein-Barr Virus Serological Reactivation with Transitioning to Systemic Lupus Erythematosus in At-Risk Individuals. Annals of the Rheumatic Diseases, 78, 1235-1241. https://doi.org/10.1136/annrheumdis-2019-215361
|
[5]
|
中国老年保健协会淋巴瘤专业委员会, 中华医学会血液学分会. 利妥昔单抗静脉快速输注中国专家共识(2020年版) [J]. 白血病∙淋巴瘤, 2021, 30(1): 1-4. https://doi.org/10.3760/cma.j.cn115356-20201030-00259
|
[6]
|
Karrar, S. and Cunninghame Graham, D.S. (2018) Review: Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us. Arthritis & Rheumatology, 70, 496-507. https://doi.org/10.1002/art.40396
|
[7]
|
Rees, F., Doherty, M., Grainge, M., Lanyon, P., Davenport, G. and Zhang, W. (2016) Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012. Arthritis Care & Research, 68, 819-827. https://doi.org/10.1002/acr.22751
|
[8]
|
Tian, J., Zhang, D., Yao, X., Huang, Y. and Lu, Q. (2022) Global Epidemiology of Systemic Lupus Erythematosus: A Comprehensive Systematic Analysis and Modelling Study. Annals of the Rheumatic Diseases, 82, 351-356. https://doi.org/10.1136/ard-2022-223035
|
[9]
|
沈南, 赵毅, 段利华, 等. 系统性红斑狼疮诊疗规范[J]. 中华内科杂志, 2023, 62(7): 775-784. https://doi.org/10.3760/cma.j.cn112138-20221027-00793
|
[10]
|
Draborg, A., Jørgensen, J., Müller, H., Nielsen, C., Jacobsen, S., Iversen, L., et al. (2012) Epstein-Barr Virus Early Antigen Diffuse (EBV-EA/D)-Directed Immunoglobulin a Antibodies in Systemic Lupus Erythematosus Patients. Scandinavian Journal of Rheumatology, 41, 280-289. https://doi.org/10.3109/03009742.2012.665944
|
[11]
|
Wood, R.A., Guthridge, L., Thurmond, E., Guthridge, C.J., Kheir, J.M., Bourn, R.L., et al. (2021) Serologic Markers of Epstein-Barr Virus Reactivation Are Associated with Increased Disease Activity, Inflammation, and Interferon Pathway Activation in Patients with Systemic Lupus Erythematosus. Journal of Translational Autoimmunity, 4, Article ID: 100117. https://doi.org/10.1016/j.jtauto.2021.100117
|
[12]
|
Hanlon, P., Avenell, A., Aucott, L. and Vickers, M.A. (2014) Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein-Barr Virus and Systemic Lupus Erythematosus. Arthritis Research & Therapy, 16, R3. https://doi.org/10.1186/ar4429
|
[13]
|
Laurynenka, V., Ding, L., Kaufman, K.M., James, J.A. and Harley, J.B. (2022) A High Prevalence of Anti-EBNA1 Heteroantibodies in Systemic Lupus Erythematosus (SLE) Supports Anti-EBNA1 as an Origin for SLE Autoantibodies. Frontiers in Immunology, 13, Article ID: 830993. https://doi.org/10.3389/fimmu.2022.830993
|
[14]
|
Li, Z., Zeng, S., Wu, H. and Zhou, Y. (2018) The Risk of Systemic Lupus Erythematosus Associated with Epstein-Barr Virus Infection: A Systematic Review and Meta-Analysis. Clinical and Experimental Medicine, 19, 23-36. https://doi.org/10.1007/s10238-018-0535-0
|
[15]
|
Piroozmand, A., Haddad Kashani, H. and Zamani, B. (2017) Correlation between Epstein-Barr Virus Infection and Disease Activity of Systemic Lupus Erythematosus: A Cross-Sectional Study. Asian Pacific Journal of Cancer Prevention, 18, 523-527. https://doi.org/10.22034/APJCP.2017.18.2.523
|
[16]
|
Han, L., Zhang, Y., Wang, Q., Xin, M., Yang, K., Lei, K., et al. (2018) Epstein-Barr Virus Infection and Type I Interferon Signature in Patients with Systemic Lupus Erythematosus. Lupus, 27, 947-954. https://doi.org/10.1177/0961203317753069
|
[17]
|
Wang, S., Wang, S. and Singh, S. (2020) Development of Systemic Lupus Erythematosus after Infectious Mononucleosis in a 64-Year-Old Woman. Journal of Investigative Medicine High Impact Case Reports, 8, 2324709620961613. https://doi.org/10.1177/2324709620961613
|
[18]
|
Iardino, A., Amar, Z. and Ahmed, Y. (2018) Epstein-Barr-Positive Classical Hodgkin Lymphoma-Associated Haemophagocytic Lymphohistocytiosis: A Rare Case. BMJ Case Reports, 2018, bcr-2018-225262. https://doi.org/10.1136/bcr-2018-225262
|
[19]
|
许书添, 董建华, 李世军. 系统性红斑狼疮合并噬血细胞综合征[J]. 肾脏病与透析肾移植杂志, 2019, 28(3): 293-297. https://doi.org/10.3969/j.issn.1006-298X.2019.03.021
|
[20]
|
Ichikawa, S., Fukuhara, N., Shirai, T., Ishii, T., Ichinohasama, R. and Harigae, H. (2020) Extranasal Extranodal NK/T-Cell Lymphoma Associated with Systemic Lupus Erythematosus. International Journal of Hematology, 112, 592-596. https://doi.org/10.1007/s12185-020-02914-w
|
[21]
|
Yamashita, H., Shimizu, A., Tsuchiya, H., Takahashi, Y., Kaneko, H., Kano, T., et al. (2014) Chronic Active Epstein-Barr Virus Infection Mimicking Autoimmune Hepatitis Exacerbation in a Patient with Systemic Lupus Erythematosus. Lupus, 23, 833-836. https://doi.org/10.1177/0961203314527367
|
[22]
|
Cohen, J.I., Jaffe, E.S., Dale, J.K., Pittaluga, S., Heslop, H.E., Rooney, C.M., et al. (2011) Characterization and Treatment of Chronic Active Epstein-Barr Virus Disease: A 28-Year Experience in the United States. Blood, 117, 5835-5849. https://doi.org/10.1182/blood-2010-11-316745
|
[23]
|
Dunmire, S.K., Verghese, P.S. and Balfour, H.H. (2018) Primary Epstein-Barr Virus Infection. Journal of Clinical Virology, 102, 84-92. https://doi.org/10.1016/j.jcv.2018.03.001
|
[24]
|
Arai, A. (2019) Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features under the 2016 WHO Classification and Mechanisms of Development. Frontiers in Pediatrics, 7, Article No. 14. https://doi.org/10.3389/fped.2019.00014
|
[25]
|
郑钰, 周菊. 慢性活动性EB病毒感染的研究进展[J]. 国际输血及血液学杂志, 2023, 46(4): 358-364. https://doi.org/10.3760/cma.j.cn511693-20220613-00094
|
[26]
|
耿研, 武丽君, 谢其冰, 等. 生物制剂在系统性红斑狼疮中应用的中国专家共识(2024版) [J]. 中华风湿病学杂志, 2024, 28(2): 78-92. https://doi.org/10.3760/cma.j.cn141217-20230711-00190-1
|
[27]
|
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S., et al. (2023) EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update. Annals of the Rheumatic Diseases, 83, 15-29. https://doi.org/10.1136/ard-2023-224762
|
[28]
|
Mok, C.C., Hamijoyo, L., Kasitanon, N., Chen, D.Y., Chen, S., Yamaoka, K., et al. (2021) The Asia-Pacific League of Associations for Rheumatology Consensus Statements on the Management of Systemic Lupus Erythematosus. The Lancet Rheumatology, 3, e517-e531. https://doi.org/10.1016/s2665-9913(21)00009-6
|
[29]
|
Marinho, A., Delgado Alves, J., Fortuna, J., Faria, R., Almeida, I., Alves, G., et al. (2023) Biological Therapy in Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Sjögren’s Syndrome: Evidence-and Practice-Based Guidance. Frontiers in Immunology, 14, Article ID: 1117699. https://doi.org/10.3389/fimmu.2023.1117699
|